Literature DB >> 1855316

Wegener's granulomatosis with renal involvement: patient survival and correlations between initial renal function, renal histology, therapy and renal outcome.

K Andrassy1, A Erb, J Koderisch, R Waldherr, E Ritz.   

Abstract

Patient survival and renal outcome were followed in 25 patients with biopsy confirmed Wegener's granulomatosis and renal involvement. Fourteen out of 25 patients required dialysis on admission, 11/25 patients did not. All patients were treated with a novel protocol comprising methylprednisolone and cyclophosphamide. The median follow-up observation was 36 months (12-113 months). With the exception of 1 patient (who died from causes not related to Wegener's granulomatosis) all patients are alive. Among the patients initially requiring dialysis (n = 14) 4 are in terminal renal failure after 0, 7, 21 and 38 months respectively. In the nondialysis group (n = 11) only 1 patient subsequently required chronic dialysis 30 months after clinical admission. Renal failure was due to non-compliance with immunosuppressive therapy in at least 2 patients. Percentage of obsolescent glomeruli and the degree of tubulointerstitial lesions, but not active glomerular lesions (crescents, necroses) predicted renal outcome. The major cause of renal functional impairment was relapse of Wegener's granulomatosis usually within 2 years after clinical remission. Therefore prolonged treatment with cyclophosphamide for at least 2 years after clinical remission is recommended. Two patients with initially negative immunohistology had a second renal biopsy which revealed de novo appearance of mesangial IgA deposits.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1855316

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  19 in total

1.  Detection of immune deposits in skin lesions of patients with Wegener's granulomatosis.

Authors:  R H Brons; M C de Jong; N K de Boer; C A Stegeman; C G Kallenberg; J W Tervaert
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

2.  Wegener's granulomatosis presenting as a pleural effusion.

Authors:  Adrian G Blundell; Simon Roe
Journal:  BMJ       Date:  2003-07-12

3.  Diagnosis and treatment of cerebral vasculitis.

Authors:  Peter Berlit
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

Review 4.  New horizons in renal vasculitis.

Authors:  J S Cameron
Journal:  Klin Wochenschr       Date:  1991-09-03

5.  Prognostic factors in Wegener's granulomatosis.

Authors:  L Briedigkeit; R Kettritz; U Göbel; R Natusch
Journal:  Postgrad Med J       Date:  1993-11       Impact factor: 2.401

Review 6.  Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much?

Authors:  J H M Beimler; K Andrassy
Journal:  Pediatr Nephrol       Date:  2004-07-15       Impact factor: 3.714

Review 7.  Vasculitis in childhood.

Authors:  I Roberti; L Reisman; J Churg
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

8.  Anti-neutrophil cytoplasmic auto-antibodies-associated vasculitis with pulmonary and renal involvement.

Authors:  G Pintos-Morell; A Roca-Comas; M A Naranjo; C Tural; E Abad; G Javier; J Prats
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

Review 9.  Expression of cytokines and growth factors in human glomerulonephritides.

Authors:  R Waldherr; I L Noronha; Z Niemir; C Krüger; H Stein; G Stumm
Journal:  Pediatr Nephrol       Date:  1993-08       Impact factor: 3.714

10.  The outcomes of patients with ESRD and ANCA-associated vasculitis in Australia and New Zealand.

Authors:  Wen Tang; Bhadran Bose; Stephen P McDonald; Carmel M Hawley; Sunil V Badve; Neil Boudville; Fiona G Brown; Philip A Clayton; Scott B Campbell; Chen Au Peh; David W Johnson
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-24       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.